The ATR checkpoint kinase coordinates cellular responses to DNA replication stress. Budding yeast contain three activators of Mec1 (the ATR orthologue); however, only TOPBP1 is known to activate ATR in vertebrates. We identified ETAA1 as a replication stress response protein in two proteomic screens. ETAA1-deficient cells accumulate double-strand breaks, sister chromatid exchanges, and other hallmarks of genome instability. They are also hypersensitive to replication stress and have increased frequencies of replication fork collapse. ETAA1 contains two RPA-interaction motifs that localize ETAA1 to stalled replication forks. It also interacts with several DNA damage response proteins including the BLM/TOP3α/RMI1/RMI2 and ATR/ATRIP complexes. It binds ATR/ATRIP directly using a motif with sequence similarity to the TOPBP1 ATR-activation domain; and like TOPBP1, ETAA1 acts as a direct ATR activator. ETAA1 functions in parallel to the TOPBP1/RAD9/HUS1/RAD1 pathway to regulate ATR and maintain genome stability. Thus, vertebrate cells contain at least two ATR-activating proteins.
The ATR checkpoint kinase coordinates cellular responses to DNA replication stress. Budding yeast contain three activators of Mec1 (the ATR orthologue); however, only TOPBP1 is known to activate ATR in vertebrates. We identified ETAA1 as a replication stress response protein in two proteomic screens. ETAA1-deficient cells accumulate double-strand breaks, sister chromatid exchanges, and other hallmarks of genome instability. They are also hypersensitive to replication stress and have increased frequencies of replication fork collapse. ETAA1 contains two RPA-interaction motifs that localize ETAA1 to stalled replication forks. It also interacts with several DNA damage response proteins including the BLM/TOP3α/RMI1/RMI2 and ATR/ATRIP complexes. It binds ATR/ATRIP directly using a motif with sequence similarity to the TOPBP1 ATR-activation domain; and like TOPBP1, ETAA1 acts as a direct ATR activator. ETAA1 functions in parallel to the TOPBP1/RAD9/HUS1/RAD1 pathway to regulate ATR and maintain genome stability. Thus, vertebrate cells contain at least two ATR-activating proteins.
DNA replication is challenged by difficult-to-replicate sequences, DNA damage, and collisions with transcriptional machinery. DNA damage response (DDR) pathways respond to replication stress to maintain genome stability, and DDR defects cause developmental disorders and cancer 1, 2 . Replication protein A (RPA) binds and protects single-stranded DNA (ssDNA) at stalled replication forks 3 . It also recruits DDR proteins such as ATRIP, which is part of the ATR/ATRIP checkpoint kinase complex [4] [5] [6] . ATR is then activated by a direct interaction with TOPBP1 (ref. 7) , which requires RHINO, and the RAD9/RAD1/HUS1 (911) and MRE11/RAD50/NBS1 (MRN) complexes for its ATRactivating function [8] [9] [10] . In budding yeast, there are at least three Mec1 ATR -activating proteins including Dpb11 (a TOPBP1 orthologue), Ddc1 and Dna2 (refs 11-14) . As yet, TOPBP1 is the only known ATR activator in mammals.
A second RPA-interacting protein at stalled forks is the BLM helicase 15 . Mutations in BLM cause Bloom syndrome 16 , and BLMdeficient cells suffer from chromosomal abnormalities such as an increase in sister chromatid exchanges (SCEs) 17, 18 . BLM functions with topoisomerase IIIα, RMI1 and RMI2 (BTR complex) to generate non-crossover products during recombination [19] [20] [21] [22] [23] [24] . TOPBP1 interacts with BLM and regulates its ability to prevent SCEs through a mechanism reported to be independent of its ATR-activating function 25, 26 . ETAA1 is an uncharacterized protein that derives its name from a study of Ewing tumour antigens 27 . Additionally, ETAA1 was identified as an ATM/ATR substrate 28 , and genome-wide association studies found that single-nucleotide polymorphisms at the ETAA1 locus increase pancreatic cancer risk 29, 30 . We find that ETAA1 is a replication stress response protein that localizes to stalled forks via a direct interaction with RPA. It also interacts with several other DDR proteins including ATR/ATRIP and the BTR complexes. ETAA1 maintains genome integrity by activating ATR using a motif that has sequence similarity to the TOPBP1 ATR-activation domain (AAD). Furthermore, ETAA1 acts in a distinct pathway from TOPBP1.
RESULTS

ETAA1 is an RPA-interacting protein that localizes to stalled forks
We recently conducted a proteomic screen utilizing iPOND (isolation of proteins on nascent DNA) combined with quantitative mass spectrometry to identify proteins enriched at stalled replication forks 31 . Samples treated with hydroxyurea (HU) for 15 min or two hours were compared with untreated cells (Fig. 1a) . Seventy-two proteins are significantly enriched at the HU-stalled forks compared with elongating forks at these times 31 . These include known DDR proteins such as ATR, RPA, BLM, SMARCAL1, BRCA1, FANCJ, MMS22L and TONSL as well as ETAA1 (Fig. 1b) . Figure 1 ETAA1 is enriched at stalled replication forks and interacts with RPA. (a,b) HEK293T cells grown in heavy-isotope media (H) and incubated with EdU and HU were compared with EdU-labelled cells grown in lightisotope media (L). Replication fork proteins were isolated and detected by iPOND and mass spectrometry (a). The log 2 of the average abundance ratio for selected proteins or complexes is depicted (b). The full iPOND-MS data set is presented elsewhere 31 . (c) Flag-RPA1 was immunopurified from HEK293T nuclear extracts and interacting proteins were identified by mass spectrometry. The table indicates the number of peptides identified for each protein. The control sample was an immunopurification from untransfected cells. The mass spectrometry experiment was performed once. (d) HEK293T cells were transfected with a Flag-ETAA1 or empty expression vector (EV), and nuclear extracts were used for immunoprecipitation with Flag antibodies. Immunoprecipitates were immunoblotted with the indicated antibodies after separation by SDS-PAGE. Representative blots from one of five independent experiments are shown. (e) Nuclear extracts from HEK293T cells were used for immunoprecipitation with RPA2 or control IgG antibodies followed by immunoblotting. Representative blots from one of two independent experiments are shown. (f-h) U2OS cells were transiently transfected with a Flag-ETAA1 expression vector and stained and imaged for Flag-ETAA1, RPA and γH2AX. Scale bars, 5 µm. In g cells were treated with 100 nM camptothecin (CPT) for 3 h. (i-k) Stable cell lines expressing GFP-Flag-ETAA1 were sorted by flow cytometry to select the 10% of cells expressing the lowest levels, stained for Flag-ETAA1, RPA, γH2AX and cyclin A as indicated, and scored for focal colocalization before and after treatment with 100 nM CPT. Error bars are s.e.m. from n = 3 experiments; Student's, two-tailed, unpaired t-test. NS, not significant. Unprocessed original scans of blots in d and e are shown in Supplementary Fig. 8 and source data for i-k are available in Supplementary  Table 1. A proteomic screen to identify RPA-interacting proteins also identified ETAA1 (Fig. 1c) . We validated the interaction by coimmunoprecipitation of RPA with Flag-ETAA1 (Fig. 1d) . Additionally, RPA2 co-immunoprecipitates with endogenous ETAA1 (Fig. 1e) .
While a previous study identified ETAA1 on the cell surface or in the cytoplasm 27 , we found that ETAA1 is localized exclusively in the nucleus. Overexpressed Flag-ETAA1 localizes to intranuclear foci in approximately 25% of cells and is diffusely pan-nuclear in others (Fig. 1f) . When it is localized to foci, ETAA1 co-localizes with RPA (Fig. 1f) . Overexpressed ETAA1 is also localized in foci when cells are treated with agents that cause replication stress including camptothecin (CPT), cisplatin (CISP) and HU ( Fig. 1g and Supplementary Fig. 1a ). These ETAA1 foci also co-localize with RPA and partially co-localize with γH2AX.
The untreated cells overexpressing ETAA1 with focal localization almost invariably contained elevated γH2AX levels, and many of the cells with pan-nuclear ETAA1 also contain elevated γH2AX suggesting that ETAA1 overexpression stimulates DNA damage signalling (Fig. 1h) . To better assess how ETAA1 localizes without overexpression, we generated stable cell lines by lentiviral infection and used fluorescence-activated cell sorting to select for the 10% of cells with the lowest GFP-ETAA1 levels. In over 95% of these cells, ETAA1 is localized diffusely throughout the nucleoplasm, but after treatment with CPT, it localizes to nuclear foci that also contain RPA and γH2AX (Fig. 1i,j) . Most cells with ETAA1 foci also contained cyclin A indicating they are in S or G2 phase (Fig. 1k) . We conclude that ETAA1 overexpression induces DNA damage signalling and ETAA1 focal accumulation, but that when it is expressed at lower levels it is primarily recruited to replication foci in response to stress.
ETAA1 binds two RPA domains to recruit it to damaged forks
To test whether the interaction with RPA recruits ETAA1 to stalled forks, we first examined a series of ETAA1 fragments for their ability to co-immunoprecipitate RPA. RPA binding is largely restricted to an ETAA1 fragment containing amino acids 571-926 (Supplementary Fig. 1b,c) . Sequence alignments identified an evolutionarily conserved motif within this fragment consisting of amino acids 900-912 that closely resembles the RPA32C-binding motif of other RPA32C-interacting proteins including SMARCAL1 and TIPIN 32, 33 (Fig. 2a ). An NMR chemical shift perturbation approach demonstrated that this ETAA1 motif binds directly to the same surface of RPA32C as previously observed for other RPA32C-interacting proteins 33, 34 (Fig. 2b,c) .
Deletion of the ETAA1 RPA32C interaction motif (ETAA1 32) greatly reduced, but did not eliminate, its ability to associate with RPA and localize to foci (Fig. 2d-f and Supplementary Fig. 1f ). Knockdown of RPA70 in cells expressing ETAA1 32 abrogated this residual localization suggesting an additional RPA-interaction surface ( Supplementary Fig. 1g ). Indeed, fragments of ETAA1 containing either residues 600-678 or 574-724 co-immunoprecipitate RPA; whereas ETAA1 fragments containing residues 2-569, 623-885 or 623-724 do not ( Supplementary Fig. 1b,d,e) , thereby narrowing the interacting motif to amino acids 600-623. This region has sequence homology to the RPA70N-interacting peptides of ATRIP, MRE11, RAD9 and p53 (Fig. 2g) 
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. NMR chemical shift mapping with this ETAA1 peptide indicates that it directly binds the basic cleft in RPA70N (Fig. 2h) . Deletion of this motif in ETAA1 (ETAA1 70) caused a slight reduction in RPA co-immunoprecipitation, and modest impairment in localization to RPA foci (Fig. 2e,f and Supplementary Fig. 1f ). Deletion or mutation of both RPA-binding motifs largely abolished RPA co-immunoprecipitation and eliminated focal accumulation (Fig. 2e,f and Supplementary Fig. 1f,h ). Thus, ETAA1 interacts with both the 70N and 32C domains of RPA, and these interactions recruit ETAA1 to stalled replication forks.
ETAA1 is a replication stress response protein
To determine whether ETAA1 has an essential function in the replication stress response, we examined the consequences of ETAA1 gene silencing. Even in untreated U2OS cells, ETAA1 knockdown caused an increase in the appearance of DNA damage markers including increased γH2AX and chromatin-associated RPA (Fig. 3a,b) . These differences were more pronounced in cells challenged with either HU or CPT, and happened in multiple cancer cell lines including HeLa, H157 and BT549 ( Supplementary Fig. 2a,b) . The increase in chromatinassociated RPA suggested that there may be additional ssDNA in ETAA1-deficient cells. Indeed, staining with BrdU antibodies in nondenaturing conditions confirmed this ssDNA increase (Fig. 3c) .
ETAA1 knockdown resulted in hypersensitivity to CPT as well as etoposide ( Fig. 3d-g ). This phenotype is not due to off-target effects since multiple short interfering RNAs (siRNAs) cause hypersensitivity ( Supplementary Fig. 2c ). Furthermore, we generated ETAA1∆ cells using CRISPR-Cas9 and again found that two independent knockout cell lines were hypersensitive to CPT and contain elevated ssDNA levels (Fig. 3c,d,h ). Additionally, expression of a wild-type ETAA1 cDNA in ETAA1∆ cells was able to complement this defect (Fig. 3i) . ETAA1-deficient cells are also hypersensitive to HU (Fig. 3j) . Hypersensitivity is not limited to ETAA1-deficient U2OS cells as knockdown of ETAA1 in most other cell types also caused hypersensitivity to both CPT and HU ( Supplementary Fig. 2d-k) . However, we did not observe increased sensitivity to ionizing radiation, cisplatin or the PARP inhibitors olaparib or BMN673 in ETAA1-deficient cells ( Supplementary Fig. 2l-o) .
In the absence of added genotoxic stress, ETAA1-deficient cell populations exhibited slightly higher percentages of cells with greater than 2n DNA content compared with controls ( Fig. 4a ) consistent with some difficulty in DNA replication. After an HU challenge, control cells rapidly resume DNA synthesis and complete the cell division cycle by 16 h. ETAA1 knockdown resulted in a slightly slower recovery with fewer cells able to complete the cell division cycle (Fig. 4b ). The differences between control and ETAA1-deficient cells were even more pronounced following treatment with CPT. These cells accumulated in early to mid S-phase, and were largely unable to complete DNA synthesis after removing CPT (Fig. 4c) .
To confirm that ETAA1-deficient cells have difficulty in DNA replication in response to replication stress, we performed DNA fibre labelling experiments. Elongation rates in unchallenged ETAA1∆ and control U2OS cells are similar (0.21 ± 0.01 µm min −1 and 0.20 ± 0.01 µm min −1 respectively). ETAA1∆ cells treated with CPT exhibit significant shortening of replication track lengths compared with controls, consistent with increased fork collapse (Fig. 4d,e) . We also observed an increase in origin firing in ETAA1∆ cells (Fig. 4f) . Furthermore, neutral comet assays indicate that ETAA1-deficient cells contain elevated levels of double-strand breaks with and without added replication stress (Fig. 4g) . Thus, we conclude that ETAA1 is needed to maintain replication fork stability.
ETAA1 interacts with multiple DDR proteins including ATR and BLM
ETAA1 lacks any predicted domain structure other than a potential coiled-coil motif. To determine whether it exerts its genome maintenance functions through protein-protein interactions we immunopurified Flag-ETAA1 and identified ETAA1-interacting proteins by mass spectrometry. As expected, all three subunits of RPA were observed in the ETAA1 immunopurifications ( Supplementary  Fig. 3a ). In addition, ETAA1 complexes contain many proteins that act at damaged replication forks including all four subunits of the BTR complex, both subunits of the ATR/ATRIP checkpoint kinase complex, BRCA1, BRCA2, HLTF, FANCM and FANCJ.
We validated that overexpressed ETAA1 interacts with BLM, HLTF, BRCA1, BRCA2 and ATR/ATRIP in co-immunoprecipitation experiments ( Supplementary Fig. 3b,c) . In contrast, we did not observe FANCD2 in the ETAA1 immunoprecipitates. ETAA1 cofractionates with BLM, TOP3α and RMI1 over a size-exclusion column ( Supplementary Fig. 3d ). Some ATR, RPA2 and HLTF also cofractionate in these high-molecular-weight complexes. Thus, ETAA1 participates in one or more large DDR protein complexes.
ETAA1 activates ATR
Since ETAA1 interacts with ATR and ATRIP we next asked whether it participates in the ATR signalling pathway by examining ATR substrate phosphorylation. We observe a modest decrease in RPA phosphorylation in U2OS cells transfected with ETAA1 siRNA (Fig. 5a ). This difference cannot be explained by decreased RPA association with damaged replication forks in ETAA1-deficient cells since there is actually an increase in chromatin-associated RPA (Fig. 3b) . Quantitation of multiple experiments confirmed the differences in RPA phosphorylation in two clones of ETAA1∆ HEK293T cells (Fig. 5b,c) . Decreased RPA phosphorylation following ETAA1 knockdown was also observed in HeLa, HCT116, H157, BT549 and A549 cells ( Supplementary Fig. 4 ). In contrast to RPA, ATR-dependent CHK1 phosphorylation was largely unaffected by ETAA1 inactivation (Fig. 5a,d and Supplementary Fig. 4 ). There is a change in ETAA1 protein migration and detection on immunoblots following treatment with CPT, consistent with it being an ATM/ATR substrate ( Supplementary Fig. 4 Figure 3 Loss of ETAA1 results in increased DNA damage and sensitivity to DNA damaging agents. (a,b) U2OS cells transfected with non-targeting (NT) or ETAA1 siRNAs were left untreated (Unt.), or treated with 2 mM HU or 100 nM CPT for 3 h. Soluble proteins were extracted with detergent prior to fixation. γH2AX and RPA intensities were quantified by immunofluorescence imaging. (c) U2OS cells transfected with siRNA or ETAA1∆U2OS cells were labelled with BrdU for 24 h and then treated with CPT for 3 h as indicated. Cells were fixed and stained with BrdU antibodies in nondenaturing conditions to measure ssDNA levels. In a-c the intensity of each nucleus and mean intensity from a representative experiment of at least two independent experiments is shown. Significance was determined by the Mann-Whitney test. * * * P < 0.001. The numbers above each sample indicate the n value, which represents the number of nuclei imaged.
(d) Immunoblot to confirm ETAA1 siRNA knockdown and gene deletion. A crossreacting protein that migrates at a similar position to ETAA1 is observed in some ETAA1 immunoblots. (e) Nuclear extracts were prepared from U2OS cells transfected with pooled ETAA1 siRNAs and ETAA1 was detected by immunoblotting after SDS-PAGE. The asterisk denotes crossreacting protein.
(f,g) U2OS cells were transfected with NT, ETAA1 or ATR siRNAs and treated with CPT or etoposide for 24 h. Viability compared with untreated cells was measured 72 h after initial addition of drug. Untreated cell viability was set at 100%. (h-j) Wild-type or ETAA1∆ U2OS cells were treated with CPT or HU for 24 h and viability was measured as in f and g. In i ETAA1∆ cells stably expressing wildtype ETAA1 were also examined. In all viability assays, the mean viability from three technical replicates of a representative experiment is graphed. Three biological replicates were completed for all panels except h, which was repeated twice. Unprocessed original scans of blots in d and e are shown in Supplementary Fig. 8 and source data for a-c,f-j are in Supplementary  Table 1 .
To understand whether the defective RPA phosphorylation in ETAA1-deficient cells is due to a defect in ATR regulation, we mapped the ATR-binding motif in ETAA1 to an amino-terminal region (Fig. 5e) . Sequence analysis identified a highly evolutionarily conserved tryptophan (residue 107) accompanied by a short region of sequence similarity to the ATR-activation domain (AAD) of TOPBP1 within this region (Fig. 5f ). In TOPBP1, this tryptophan is essential to bind and activate ATR 7 . Mutation of ETAA1 Trp107 to alanine reduced the ability of ETAA1 to co-immunoprecipitate ATR (Fig. 5e ).
On the basis of the similarity to TOPBP1 and the reduction in RPA phosphorylation in ETAA1-deficient cells, we considered the possibility that ETAA1 acts as a direct ATR activator. Indeed, like the TOPBP1-AAD, an ETAA1 fragment containing amino acids 75-250 purified from Escherichia coli strongly activates ATR in vitro (Fig. 5g,h ). This activation requires Trp107, other fragments of ETAA1 do not stimulate ATR, and an ATR inhibitor eliminates the kinase activity indicating specificity. Thus, ETAA1 contains an AAD within amino acids 75-250, and ETAA1 is a direct ATR activator like TOPBP1.
We hypothesized that the increased DNA damage signalling that we observed in cells overexpressing ETAA1 (Fig. 1) could be due to ectopic activation of ATR like what happens following TOPBP1-AAD overexpression 7, 36, 37 . It is also possible that ETAA1 overexpression could cause damage by interfering with RPA function yielding an RPA-exhaustion-like phenotype 38 . To test these ideas, we overexpressed various ETAA1 proteins and measured γH2AX. The high level of γH2AX induced by wild-type ETAA1 is reduced but not eliminated by mutation of the RPA-interacting motifs ( Supplementary  Fig. 5a,c,e) . These proteins are expressed at least tenfold higher than the stable ETAA1-expressing cell lines that lack spontaneous ETAA1 foci ( Supplementary Fig. 5f ). A fragment of ETAA1 missing the ETAA1-AAD (amino acids 251-926) does not cause γH2AX despite its ability to localize to RPA foci ( Supplementary Fig. 5b-d) .
The ETAA1-AAD by itself is sufficient to induce γH2AX when highly overexpressed and the level of γH2AX induced is correlated with its expression level ( Supplementary Fig. 5b,c,e,g ). In contrast, the ETAA1-AAD containing the W107A mutation largely does not induce damage signalling (Supplementary Fig. 5b,c,h ). Thus, we conclude that overexpression of ETAA1 promotes DNA damage signalling by binding both RPA and ATR, and high levels of expression of just the ETAA1-AAD are sufficient to activate ATR. ETAA1 requires its RPA-interaction and ATR-activation domains to maintain genome stability We next tested whether the ETAA1 replication stress response functions are dependent on its ability to bind RPA and activate ATR. First, we complemented the ETAA1∆ cells with wild-type or RPAbinding mutant GFP-ETAA1 complementary DNA. Cells were sorted to select for the 10% of cells with the lowest expression of GFP-ETAA1 proteins ( Supplementary Fig. 6a,b) . While wild-type ETAA1 fully complements the CPT hypersensitivity of ETAA1∆ cells, the ETAA1-RPA-expressing cells remain modestly hypersensitive (Supplementary Fig. 6c) . Furthermore, ETAA1∆ cells also exhibited significantly higher levels of genome instability as measured by micronuclei formation, which could be rescued by wild-type but not RPA-bindingdefective ETAA1 (Supplementary Fig. 6d ). Thus, we conclude that RPA binding is needed for ETAA1 to maintain genome stability.
To examine the cellular functions of the ETAA1-AAD and avoid problems caused by ETAA1 overexpression we devised a strategy to delete the AAD in the endogenous ETAA1 gene locus. A portion of the AAD including Trp107 is encoded by ETAA1 exon 2. Cas9-mediated deletion of exon 2 using two guide RNAs spanning the 5 intronexon boundary results in the production of an ETAA1 messenger RNA in which exon 1 splices to exon 3. This mutation maintains the open reading frame and results in the expression of an ETAA1 exon2 protein missing residues 76-118 that remains capable of binding RPA (Fig. 6a,b) .
ETAA1∆exon2 cells show a very similar reduction in DNA replication track lengths as the ETAA1∆ cells in response to a CPT challenge (Fig. 6c,d) . They also exhibit a reduction in RPA phosphorylation (Fig. 6e,f,g ), although there is no obvious defect in CHK1 or MCM2 phosphorylation (Fig. 6e,h ).
ETAA1-deficient cells exhibit elevated levels of SCEs
Many of the other proteins that ETAA1 associates with are involved in recombination-based repair mechanisms. However, we did not observe a significant hypersensitivity of ETAA1-deficient cells to ionizing radiation (Supplementary Fig. 2l ) or PARP inhibition respectively. One of two biological replicates is shown. (e-h) Wild-type, ETAA1∆ and ETAA1∆exon2 HEK293T cells were treated with 100 nM CPT for 0, 4 or 8 h. Cell lysates were immunoblotted for phosphorylated and total RPA and CHK1. Black bars are the mean from n = 3, 4 and 5 experiments in f,g and h respectively. The wild-type and ETAA1∆ data in c and d are the same as in Fig. 4 since the wild-type, ETAA1∆ and ETAA1∆exon2 cells were compared in the same experiments. Unprocessed original scans of blots in b and e are shown in Supplementary Fig. 8 , and source data for c,d,f,g and h are provided in Supplementary Table 1. ( Supplementary Fig. 2n,o) . The interaction of ETAA1 with both HLTF and the BTR complex was of interest since the budding yeast orthologue of HLTF (RAD5) promotes template switching, while the BLM orthologue (SGS1) helps to dissolve these repair intermediates to prevent crossovers 39 . The human BTR complex also promotes non-crossover repair outcomes during replication fork repair 20, 23, 40 . Thus, a defining characteristic of BLM-deficient cells is a striking increase in SCEs. Indeed, BLM silencing increases SCEs by approximately 10-fold while silencing ETAA1 resulted in a 2.5-fold increase (Fig. 7a,b) . ETAA1∆ cells also exhibited an increased frequency of SCEs compared with controls (Fig. 7c) . The frequency of SCEs in ETAA1∆ and wild-type cells transfected with BLM siRNA was not different, suggesting an epistatic relationship (Fig. 7c) . Both ETAA1 and BLM deficiency also yield increased levels of micronuclei, and again ETAA1 and BLM are epistatic for this phenotype (Fig. 7d,e) . ETAA1∆exon2 cell lines also exhibit elevated levels of micronuclei and SCEs similar to the ETAA1∆ cells, indicating that ETAA1 must be able to activate ATR to prevent genetic instability (Fig. 7f,g ).
ETAA1 and TOPBP1 function in distinct pathways
ETAA1 is similar to TOPBP1 in that both activate ATR, complex with BLM, and prevent SCEs. Thus, we considered whether they function in the same or distinct pathways. Unlike ETAA1 deficiency, TOPBP1 knockdown has a strong effect on ATR-dependent CHK1 
(29) and SCEs (g) were scored in wild-type, ETAA1∆, and two independent ETAA1∆exon2 U2OS cell clones. Mean, s.e.m., and number of metaphases analysed (n value) are presented. Significance in e,f and g was determined by ANOVA with a Dunnett multiple comparison post-test. Source data for b,c,e,f and g are provided in Supplementary Table 1. phosphorylation (Fig. 8a) . However, we consistently observe that RPA phosphorylation is primarily dependent on ETAA1 and only modestly affected by TOPBP1 knockdown. We also did not observe TOPBP1 in our ETAA1 purifications, suggesting that they function in distinct pathways. TOPBP1 binding and ATR activation requires ATR amino acids between the kinase and FATC domains called the PIKK regulatory domain (PRD) 41 . Mutations in the PRD do not interfere with the basal activity of ATR, but they greatly reduce the ability of TOPBP1 to activate ATR 41 . Like TOPBP1, ETAA1-dependent ATR activation is greatly diminished by ATR PRD mutations (Fig. 8b) . This result and the similarity of the AAD motifs suggest that ETAA1 and TOPBP1 utilize a similar mechanism to activate ATR.
ETAA1 requires its AAD to prevent SCEs (Fig. 7g) , while TOPBP1 is reported to regulate SCEs independently of its AAD 25, 26 . TOPBP1 knockdown yields a similar increase in SCEs as ETAA1 deficiency and TOPBP1 knockdown in ETAA1∆ cells further increases SCE frequency above that of either TOPBP1 or ETAA1 deficiency alone, again consistent with operation in distinct pathways (Fig. 8c) . Previous studies have made conflicting conclusions about whether TOPBP1 regulation of BLM is through changing its stability 25, 26 . We did not observe large changes in BLM protein levels when we knocked down TOPBP1, and ETAA1 deficiency also does not alter BLM protein levels ( Supplementary Fig. 7) .
Finally, if ETAA1 and TOPBP1 pathways are distinct we would expect loss of ETAA1 to be synthetically lethal with TOPBP1 or 911 deficiency. Indeed, knockdown of TOPBP1 or RAD9 resulted in decreased survival of ETAA1∆ cells following a challenge with CPT (Fig. 8d) . Taken together, these data indicate that ETAA1 and TOPBP1 function in distinct pathways to activate ATR signalling and maintain genome stability.
DISCUSSION
Previous studies identified three ATR (Mec1) activators in budding yeast (Dpb11, Ddc1 and Dna2) [12] [13] [14] . We now report that human cells contain at least two ATR activators, TOPBP1 and ETAA1. This conclusion is consistent with that of the accompanying paper that independently identified ETAA1 as an ATR activator Dpb11 functional orthologue; however, ETAA1 does not resemble any of the yeast ATR-activating proteins outside of the key residues needed to activate ATR.
TOPBP1 and ETAA1 act in separate pathways to maintain genome integrity and regulate ATR. The ability of ETAA1 to bind directly to RPA distinguishes it from TOPBP1, which requires the MRN and 911 complexes for its recruitment and ATR-activating function 10, 43 . 911 is loaded on DNA gaps only when a free 5' end is available at the ssDNA-dsDNA junction. Thus, extensive ssDNA generation may not generate more 911-TOPBP1-ATR signalling complexes. We propose that ETAA1 helps to propagate ATR activation along stretches of ssDNA since it can bind RPA and function independently of 911 (Fig. 8e) .
RPA is particularly dependent on ETAA1 for phosphorylation; whereas other ATR substrates such as CHK1 and MCM2 are more dependent on TOPBP1. CHK1 phosphorylation requires the replisome component CLASPIN 44 , and MCM2 is part of the replicative helicase. Thus, it is possible that the proximity to the replisome where it may be more likely to have a 5' DNA junction to load 911/TOPBP1 could determine ETAA1 versus TOPBP1 dependency. The ability of TOPBP1 and ETAA1 to interact with DDR proteins or their relative level of expression, which differs considerably across cell types, may be additional levels of substrate selection.
In conclusion, ETAA1 is a replication stress response protein needed to maintain genome stability. ETAA1 complexes with multiple DDR proteins and one mechanism of ETAA1 action in the replication stress response is as a direct ATR activator. The requirement for ETAA1 to maintain genome stability could be why polymorphisms in the ETAA1 locus increase the risk of pancreatic cancer 29, 30 .
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METHODS
Cell culture. U2OS, HeLa and HEK293T cells were cultured in DMEM + 7.5% FBS. A549, BT549 and H157 cells were cultured in RPMI + 10% FBS. HCT116 cells were cultured in McCoy's 5A media + 10% FBS. Cell lines were from ATCC. The H157 lung carcinoma cells deposited with ATCC are known to be contaminated with H1264 lung carcinoma cells. This is unlikely to affect the results obtained with this cell line since either H157 or H1264 cells could have been used to make the conclusion that ETAA1 is needed in multiple cell types to promote ATR signalling. None of the other cell lines used in this study were found in the database of commonly misidentified cell lines that is maintained by ICLAC and NCBI. Cell lines were not authenticated or tested for mycoplasma contamination after receipt. Plasmid transfections were performed with polyethylenimine. siRNA transfections were performed with Dharmafect1 (Dharmacon) for U2OS, A549, BT549 and H157 cells and RNAiMax (Thermo Fisher) for HeLa and HCT116 cells. ETAA1 siRNA sequences include: 3 -GAGAAUGGCUAAAGCACGA-5 , 3 -CAUAAUAUAGUU CCCGAAA-5 , 3 -UAGCAAUUAUGUACGGAUA-5 and 3 -GAGAAUGGCUA AAGCACGA-5 . HEK293T and U2OS ETAA1∆ and ETAA1∆exon2 cells were generated using CRISPR-Cas9. Briefly, cells were transfected with pSpCas9(BB)-2A-Puro (Addgene plasmid no. 48139) containing guide RNAs targeting the intronexon junction of the fifth exon of ETAA1 (3 ATTTGATAGATCAAAACTG-5 , 3 GAAGAAGAACTTATGAAAC-5 ) or the second ETAA1 exon (3 GTTCTCCTAATGATCCAGA-5 , 3 CTAGTCAGATAATAGCATC-5 ) and selected with 2 µg ml −1 puromycin for two days prior to plating for individual clones. Deletion of the exon 5 splice junction is predicted to cause out-of-frame splicing and nonsense-mediated decay. Deletion of the exon 2 splice junction is predicted to yield an in-frame splicing of exons 1 and 3. Homozygous editing of the ETAA1 loci was confirmed by PCR and sequencing. Furthermore, expression of an ETAA1 exon2 mRNA was confirmed by RT-PCR and sequencing the cDNA.
Complementation of ETAA1∆ cells with cDNA expression vectors was completed by lentiviral infection, selection for the linked puromycin resistance cassette, and then sorting for the 10% of cells with the lowest expression of the GFPtagged ETAA1 proteins.
Antibodies and immunofluorescence.
The following antibodies were used: BLM (1:1,000, sc-7790, C-18, Santa Cruz), RPA32 (1:1,000, ab2175, 9H8, Abcam), RPA70 (1:1,000, 2267, Cell Signaling), pRPA32 S4/8 (1:1,000, A300-245A2, Bethyl), pRPA32 S33 (1:1,000, IHC-00421, Bethyl and NB100-54, Novus), Flag (1:1,000, F-3165, M2 and F7425, Sigma), ATR (1:1,000, SC-1887, N-19, Santa Cruz), ATRIP (1:1,000, 403, custom), CHK1 (1:750, sc-8408, G4, Santa Cruz), CHK1pS317 (1:1,000, 2344S, Cell Signaling), MCM2 (1:1,000, 39289, BM28, BDTransduction Labs), pMCM2S108 (1:10,000, IHC-00014, Bethyl), GAPDH (1:10,000, sc20357, Santa Cruz), TOP3A (1:1,000, sc-11257,N-20, Santa Cruz), RMI1 (1:1,000, A300-631A-M, Bethyl), RMI2 (1:1,000, ab122685, Abcam), HLTF (1:1,000, gift from K. Cimprich, Stanford University, USA), FANCD2 (1:1,000, sc-20022, Fi17, Santa Cruz), BRCA1 (1:1,000, OP-92, Calbiochem), BRCA2 (1:1,000, OP95, Calbiochem), TOPBP1 (1:1,000, A300-111A-1, BL893, Bethyl), Cyclin A (1:1,000, sc-751, Santa Cruz). Custom ETAA1 antibodies were produced by Covance. Quantitative immunoblotting was performed using an Odyssey instrument. Unless otherwise stated, immunoblots are representative of at least two biological replicates. For immunofluorescence experiments, U2OS, HeLa, H157 or BT549 cells were fixed in 3% paraformaldehyde. Slides were blocked with 5% BSA in PBS and incubated with antibody. Immunofluorescent images were obtained with a Zeiss Axioplan or Nikon microscope with fixed camera exposure times. RPA, γH2AX and ETAA1 intensities were determined using Cell Profiler software. In some cases, at least 1,000 cells were manually scored for whether they contained at least five foci by using blinded samples.
Flow cytometry. Three days after siRNA transfection, U2OS cells were treated with 2 mM HU or 100 nM CPT. After 24 h cells were washed and fresh medium was added. Cells were harvested every 2 h after addition of fresh medium for 16 h. For each sample, 10 6 cells were fixed in cold ethanol, treated with RNase A, stained with propidium iodide and analysed on a BD Biosciences FACSCalibur.
Viability assays. Viability assays were performed in U2OS cells transfected with siRNAs or ETAA1 knockout cell lines generated by CRISPR-Cas9. Cells were treated with increasing concentrations of drug and viability was measured 72 h later with Alamar Blue. PARP inhibitors were left in the growth media for the duration of the experiment. HU, CPT, etoposide and cisplatin sensitivity assays were performed after a 24-h challenge. All viability measurements are presented as a percentage of the untreated control. For clonogenic assays, cells were plated and treated with drug for 24 h. Colonies were scored approximately two weeks after removal of drug by staining with methylene blue (50% methanol, 48% water, 2% methylene blue).
SILAC-iPOND-MS.
The SILAC-iPOND-MS was carried out as described previously and the iPOND data in Fig. 1 were extracted from previously published data sets 30 .
Co-immunoprecipitation and mass spectrometry. HEK293T cells were transfected with Flag-GFP-NLS-ETAA1 constructs and nuclear extracts were prepared. ETAA1 was immunoprecipitated using Flag antibody conjugated to protein G Dynabeads. ETAA1 and interacting proteins were eluted by addition of Flag peptide. Coprecipitating proteins were identified by SDS-PAGE followed by immunoblotting or directly by two-dimensional liquid chromatography tandem mass spectrometry. The nuclear extracts were treated with benzonase and RNAse in one of the two replicates of the Flag-ETAA1 mass spectrometry experiment to remove any contaminating nucleic acids.
Gel filtration. HEK293T nuclear extract was loaded onto a Superdex 200 column equilibrated with gel filtration buffer (150 mM NaCl, 25 mM HEPES pH 7.5, 10% glycerol, 1 mM dithiothreitol) and eluted at 0.20 ml min −1 with collection of 0.5 ml fractions. Equal volumes of each fraction were immunoblotted directly or immunoprecipitated with anti-ETAA1 antibodies prior to the ETAA1 immunoblot.
Sister chromatid exchange and micronuclei assays. Cells transfected with siRNAs were labelled with 10 µM BrdU for two cell cycles (48 h). Colcemid was added to a final concentration of 150 ng ml −1 for 1 h and cells were harvested and metaphases prepared as previously described 45 . Cells were stained with 0.1 mg ml −1 acridine orange and mounted in Sorenson buffer (pH 6.8, 0.1 M Na 2 HPO 4 , 0.1 M NaH 2 PO 4 ) and visualized using a Zeiss Axioplan Microscope. Approximately 1,000 chromosomes were scored per condition. Micronuclei were scored manually after imaging more than 1,500 nuclei with 4 ,6-diamidino-2-phenylindole (DAPI). All samples were blinded to the experimenter. transfected with an ETAA1 expression vector missing the C-terminal RPA32 interaction motif (ETAA1D32) in combination with non-targeting or RPA siRNA and imaged for ETAA1 and RPA localization after a challenge with 100 mM CPT. (h) ETAA1D cells were transduced with lentivirus to express empty vector (GFP-Flag), GFP-Flag-ETAA1 (WT), or GFP-Flag-ETAA1 with point mutations (residues 606-611 mutated from DVDDDL to NAAIRS) in the RPA70N motif and deletion of the ETAA1-RPA32C (deletion of residues 885-926) interaction motif (ETAA1∆RPA). Cells were treated with 100 nM CPT for 3 hrs. RPA, and Flag-GPF-ETAA1 were visualized by immunofluorescence. Representative images from one of two independent experiments in g and h are shown. Scale bars are 5 µm. Unprocessed original scans of blots in c, d and e are shown in Supplementary Fig. 8 , and source data for f is in Supplemental Table 1 .
NMR analysis.
[HU] (mM) 0. Supplemental Figure 8 Uncropped images of immunoblots from other figures.
